Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2013

View Archived Issues

Positive safety and efficacy data reported for ORM-12741 in phase IIa trial

Eisai's novel BACE1 inhibitor shows efficacy in reducing Abeta levels in vivo

SBI Pharmaceuticals' malignant glioma diagnostic approved in Japan

Trius' phase III tedizolid study in ABSSSI meets primary endpoint

Novel gene therapy may protect against Parkinson's disease

DNA-based epitope vaccine for AD tested in rabbits

Incyte Corp. patents novel PI3Kdelta inhibitors

IRM and Novartis divulge new PDGFR inhibitors

Osteoprotegerin as a predictor of mortality in CS complicating AMI

ReNeuron cleared to begin stem cell therapy trial in the U.K.

SymBio Pharmaceuticals begins phase I MDS trial in Japan

PICASSO 3 results lead ZIOPHARM Oncology to refocus development efforts

iBio to advance iBioLaunch-produced recombinant C1 inhibitor to clinical development

rhCDNF demonstrates improvement in MPTP mouse model of PD

Catabasis begins phase I trial of CAT-2003 for severe hypertriglyceridemia

Galapagos provides update on development portfolio

Takeda files for approval of lansoprazole/low-dose aspirin in Japan

Phytopharm provides update on strategic review

Scientists at Merck & Co. present new agents for hepatitis

Otsuka files NDA for multidrug-resistant tuberculosis drug in Japan

RedHill Biopharma and IntelGenx submit NDA for RHB-103 oral thin film

POZEN applies for FDA approval of PA-32540 and PA-8140

Aastrom Biosciences shifts focus

Novel PDE2A/PDE10A inhibitors patented by Lundbeck

EMA accepts ospemifene MAA

Pfizer obtains conditional marketing authorization for Bosulif in Europe

FDA approves Biogen Idec's Tecfidera as first-line oral treatment for MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....